Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences by Deissler, Heidrun L et al.
Actions of bevacizumab and ranibizumab on




2 Gabriele E Lang
1
ABSTRACT
Background Retinal endothelial cells are crucially
involved in the genesis of diabetic retinopathy which is
treated with vascular endothelial growth factor (VEGF)
inhibitors. Of these, ranibizumab can completely restore
VEGF-induced effects on immortalised bovine retinal
endothelial cells (iBREC). In most experiments supporting
diabetic retinopathy therapy with bevacizumab, only non-
retinal EC or retinal pigment epithelial cells have been
used. Also, bevacizumab but not ranibizumab can
accumulate in retinal pigment epithelial cells.
Objective To investigate the effects of bevacizumab on
VEGF-induced changes of iBREC properties and potential
uptake and accumulation of both inhibitors.
Methods Uptake of VEGF inhibitors by iBREC with or
without pretreatment with VEGF165 was visualised by
immunoﬂuorescence staining and western blot analyses.
Measured transendothelial resistance (TER) of iBREC
(6VEGF165) showed effects on permeability, indicated
also by the western blot-determined tight junction
protein claudin-1. The inﬂuence of bevacizumab on
proliferation and migration of iBREC was studied in the
presence and absence of VEGF165.
Results Bevacizumab strongly inhibited VEGF-stimulated
and basal migration, but was less efﬁcient than
ranibizumab in inhibiting VEGF-induced proliferation or
restoring the VEGF-induced decrease of TER and claudin-
1. This ability was completely lost after storage of
bevacizumab for 4 weeks at 48C. Ranibizumab and
bevacizumab were detectable in whole cell extracts after
treatment for at least 1 h; bevacizumab accumulated
during prolonged treatment. Ranibizumab was found in
the membrane/organelle fraction, whereas bevacizumab
was associated with the cytoskeleton.
Conclusion Both inhibitors had similar effects on retinal
endothelial cells; however, some differences were
recognised. Although barrier properties were not
affected by internalised bevacizumab in vitro, potential
adverse effects due to accumulation after repetitive
intravitreal injections remain to be investigated.
INTRODUCTION
Vascular endothelial growth factor (VEGF) and its
receptors are promising targets for treating diabetic
retinopathy (DR), particularly diabetic macular
oedema (DME), as elevated levels of VEGF have
been found in the vitreous ﬂuid and retinal vascu-
lature of patients.
1e3 Accordingly, the VEGF-binding
antibody fragment ranibizumab has recently been
approved for DME therapy; the humanised VEGF-
speciﬁc antibody bevacizumab is also used.
45The
most important variant, VEGF165, not only elevates
permeability of retinal endothelial cells (REC), likely
leading to DME in vivo, but also stimulates prolif-
eration and migration of REC to initiate
neovascularisation.
6e12 Several in vitro studies have
conﬁrmed that VEGF-stimulated proliferation of
retinal or choroidal endothelial cells is inhibited by
ranibizumab or bevacizumab.
10 12 13 Increased
permeability of immortalised bovine REC (iBREC)
induced by long-term exposure to VEGF165,a c c o m -
panied by loss of plasma membrane-localised tight
junction (TJ) protein claudin-1, was completely
restored by treatment with ranibizumab, even in
the presence of other growth factors.
91 4Despite
their similarity, deviating pharmacological activities
of the VEGF inhibitors may result from differences
in accumulation in relevant cell types, which has
been shown for retinal pigment epithelial (RPE)
cells: only bevacizumab was transported through
the plasma membrane and its intracellular amounts
increased over several days.
15 Sufﬁciently accumu-
lated bevacizumab affected phagocytotic uptake of
photoreceptor outer segments by RPE cells and also
their barrier function.
16 17 In contrast, ranibizumab
only transiently impaired the barrier formed by
these cells, and their phagocytotic uptake was not
altered by exposure to this drug.
16 17 These ﬁndings
suggest that mechanisms of therapeutic activity of
both VEGF inhibitors involving REC might also
differ in relevant details. Therefore we used the
established model cell line iBREC to investigate the
efﬁciency of bevacizumab to restore VEGF-induced
effects on proliferation, migration and barrier func-
tion. In addition, uptake of both VEGF inhibitors by
iBREC and potential consequences were studied.
MATERIALS AND METHODS
Reagents, antibodies and media
Recombinant human VEGF165 was obtained from
R&D Systems (Wiesbaden, Germany). Ranibi-
zumab (Lucentis, 10 mg/ml), the Fab fragment of
a humanised VEGF-binding antibody, was a gift
from Novartis Pharma (Nuremberg, Germany).
18
The anti-VEGF antibody bevacizumab (Avastin,
25 mg/ml) was purchased from Roche Pharma
(Basel, Switzerland); aliquot parts were stored in
inert plastic vessels at 48C.
19 Alternatively, bevaci-
zumab was repackaged at the pharmacy of the
University Hospital Ulm and provided in syringes
which were stored at 48C. Rabbit polyclonal anti-
bodies binding to human claudin-1 (JAY.8) or
claudin-5 (Z43.JK) and AlexaFluor 594-conjugated
detection antibodies were from Invitrogen (Karls-
ruhe, Germany); goat polyclonal antibodies
directed against canine VEGF (cross-reacting with
bovine VEGF) were from R&D Systems.
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Laboratory scienceCultivation of iBREC and treatment with growth factors and
inhibitors
Telomerase-immortalised microvascular endothelial cells from
bovine retina (iBREC) were cultivated in endothelial cell growth
medium (ECGM; Promocell, Heidelberg, Germany) supple-
mented with 0.4% endothelial cells growth supplement/H,
10 ng/ml epidermal growth factor and 103 nM hydrocortisone
and 5% fetal calf serum (FCS) as described previously.
14 20
Prior to experiments with conﬂuent iBREC, the serum
concentration of ECGM was reduced to 0.25% FCS for 24 h.
After treatment with 100 ng/ml VEGF165 for 2 days, cells were
incubated with medium containing 100 ng/ml VEGF165, and
100 mg/ml ranibizumab or 250 mg/ml bevacizumab, for at least
24 h before cell extracts were prepared.
14 To study the effect of
VEGF inhibitors on unstimulated cells, iBREC were kept in
medium with 100 mg/ml ranibizumab or 250 mg/ml bevaci-
zumab for periods from 30 min to 6 days.
Preparation of subcellular fractions and western blot analyses
Subcellular fractions were prepared with the ProteoExtract
Subcellular Proteome Extraction Kit (Merck, Darmstadt,
Germany) according to the manufacturer’s instructions, yielding
proteins localised in the cytosol, in membranes/organelles, in the
nucleus, and in components of the cytoskeleton. Cytosolic,
membrane and nuclear fractions were cleared by additional
centrifugation (100003g, 48C) for 10 min.
Western blot analyses of whole cell extracts or subcellular
fractions were performed as described.
11 14 Analyses of ranibi-
zumab and bevacizumab were based on immunoreactivity of
polyclonal antibodies (coupled to horseradish peroxidise) with
human IgG (1:20000, Invitrogen). For semi-quantitative assess-
ment, speciﬁc chemiluminescence signals were compared to
those of standard samples used in the range 0.5d50 ng.
Immunoﬂuorescence staining
Conﬂuent monolayers of iBREC on ﬁbronectin-coated two-
chamber slides (Nunc, Wiesbaden, Germany) were treated with
effectors as described above and antigens were visualised by
immunoﬂuorescence staining.
10 Internalised ranibizumab or
bevacizumab were stained by incubation with AlexaFluor594-
coupled polyclonal antibodies (1:10000) against human IgG for
90 min after blocking with 10% FCS/PBS for 30 min. To deter-
mine the limit of detection, diluted samples of the inhibitors
were spotted on an appropriate membrane and processed alike.
Transendothelial electrical resistance of cell layers
To assess paracellular permeability of iBREC, transendothelial
electrical resistance (TER) was measured as described previ-
ously.
11 14 Normalised TER values were calculated in relation to
the TER measured in low serum medium immediately before
the medium was replaced by fresh medium containing effectors.
Cell migration and proliferation assays
Cell migration assays were performed in a modiﬁed Boyden
chamber; enzymatic conversion of WST-1 (Roche), indicative of
proliferating cells, was measured 24 h after addition of effectors
to iBREC as described previously.
10 Values were normalised to
those obtained with control cells not treated with effectors.
General considerations and statistical analyses
In all experiments, control cells were processed identically in
medium only lacking the effector(s) under investigation. All
experiments were repeated at least three times; in each experi-
ment, data were generated from multiple replicates. The
ManneWhitney U test was used to compare sets of experi-
mental data; differences resulting in p values below 0.05 were
considered signiﬁcant. Results are presented either as conven-
tional box-whiskers diagrams showing means and percentiles
(75%, 25%) or by providing means and corresponding standard
deviations.
RESULTS
Bevacizumab inhibits VEGF165-induced proliferation and
migration
Our previous studies showed that stimulation of proliferation
and migration of iBREC with VEGF165 is completely suppressed
by 100 mg/ml ranibizumab.
10 To compare the inhibitory effect of
the related drug bevacizumab, serum-starved iBREC were
exposed to VEGF165 and bevacizumab for 24 h before conversion
of WST-1 was determined as a measure of cell proliferation.
Only partial inhibition of VEGF-stimulated proliferation by
bevacizumab was observed under these conditions (ﬁgure 1A).
VEGF-stimulated migration of iBREC towards ﬁbronectin in
a modiﬁed Boyden chamber was not only strongly inhibited by
bevacizumab, but was even driven below basal migration rates
(ﬁgure 1B). The effect of bevacizumab on proliferation or
migration of iBREC was not dependent on time and conditions
of its storage prior to the experiments.
Bevacizumab restores a VEGF165-impaired iBREC barrier
In accordance with previous investigations, treatment of iBREC
with VEGF165 signiﬁcantly decreased the TER within 2 days
(ﬁgure 2A).
14 After addition of bevacizumab to the VEGF-
pretreated cells, TER increased within 1 day but reached normal
values only during prolonged exposure (ﬁgure 2A), whereas
almost complete reversion was achieved after 1 day with rani-
bizumab. Like ranibizumab, bevacizumab completely reinstated
the VEGF-induced loss of claudin-1 (ﬁgure 2B,C). This effect of
potential therapeutic relevance on TJs was entirely lost after
Figure 1 Vascular endothelial growth factor (VEGF165)-stimulated
proliferation and migration of immortalised bovine retinal endothelial
cells (iBREC) is inhibited by bevacizumab. (A) Serum-starved iBREC
were incubated with VEGF165 in the presence or absence of
bevacizumab and their proliferation was measured after 24 h. (B) iBREC
migration towards ﬁbronectin was measured in a modiﬁed Boyden-
chamber. VEGF165-stimulated migration was inhibited by bevacizumab
below the level of basal migration.
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Laboratory sciencestorage of the repackaged solutions of bevacizumab at 48C for
more than 4 weeks (ﬁgure 2B). In contrast, ranibizumab effec-
tively reverted the loss of claudin-1 when stored under the same
conditions (ﬁgure 2C). Whereas the capacity of bevacizumab to
revert VEGF-induced vanishing of claudin-1 was dependent on
its storage history, prevention of this process was not affected,
even after prolonged storage (ﬁgure 2D). Western blot analyses
conﬁrmed that neither protein fragmentation nor formation of
aggregates occurred during long-term storage of bevacizumab or
ranibizumab solutions.
Uptake of bevacizumab and ranibizumab by iBREC
First we conﬁrmed that the Fab fragment ranibizumab and the
whole antibody bevacizumab were both bound by polyclonal
antibodies against human IgG, and that the detection limits
(25 ng for immunoﬂuorescence staining, 0.5 ng for western blot
analyses) were low enough. To monitor uptake by iBREC, their
conﬂuent monolayers were incubated with bevacizumab or
ranibizumab for various periods from several hours to 6 days.
Internalised drugs were visualised by immunoﬂuorescence
staining or determined in cell lysates (ﬁgures 3 and 4). After
treatment for 30 min, a diffuse bevacizumab-speciﬁc staining
was observed, which was focused around the nucleus in cells
that had been exposed longer to this antibody (ﬁgure 3, right
column). Staining intensity and pattern were not affected by
pretreatment with VEGF165 for 1 day. In contrast to the
observed uptake of bevacizumab, considerable amounts of
ranibizumab were not detected by immunoﬂuorescence staining
in iBREC treated with this antibody fragment (ﬁgure 3, middle
column). These results were conﬁrmed by western blot analyses
of whole cell extracts of iBREC treated with the VEGF inhibi-
tors: bevacizumab was detectable after 1 h and accumulated
during further incubation until day 6 (ﬁgure 4A). In contrast,
less ranibizumab was taken up slower by iBREC and, despite
prolonged incubation with the antibody fragment, the amount
of internalised ranibizumab remained constant (ﬁgure 4B). Most
of the bevacizumab absorbed by iBREC was found associated
with the cytoskeleton and a smaller part in the subcellular
fraction consisting of membranes and organelles (ﬁgures 3 and
4C), whereas ranibizumab was present in the membrane/
organelle fraction but did not co-occur with cytoskeleton
proteins (ﬁgure 4D). The different subcellular localisations of
ranibizumab and bevacizumab were not affected by extended
exposure or pretreatment with VEGF165. In these experiments,
VEGF was mainly detected in the membrane/organelle fraction
in the absence or presence of VEGF inhibitors.
Effects of bevacizumab and ranibizumab on barrier, migration
and proliferation of unstimulated iBREC
Destabilisation of the cell barrier, as reported for bevacizumab-
treated RPE cells, was not observed when TER of iBREC was
monitored during incubation with ranibizumab or bevacizumab
for up to 6 days (ﬁgure 5A).
17 Constant localisation of the tight-
junction proteins claudin-1 and claudin-5 in the plasma
Figure 2 Vascular endothelial growth factor (VEGF165)-induced decrease of transendothelial resistance (TER) and claudin-1 expression are restored
by bevacizumab. Conﬂuent immortalised bovine retinal endothelial cells (iBREC) were treated with 100 ng/ml VEGF165 for 2 days, before 250 mg/ml
bevacizumab or 100 mg/ml ranibizumab were added. (A) TER was measured at indicated time points after start of incubation with VEGF165 and
inhibitor. Complete reversion of TER-decrease was achieved after treatment with bevacizumab for 1.5 days or with ranibizumab for 1 day. (B) iBREC
pretreated with VEGF165 were exposed to bevacizumab which had been stored for 2, 4 or 6 weeks at 48C and expression of claudin-1 was analysed by
western blot 24 h later. The ability of bevacizumab to restore lost claudin-1 vanished during prolonged storage at 48C. (C) iBREC were treated as
described in (B) but ranibizumab stored at 48C for 6 weeks was used to restore claudin-1 completely. (D) iBREC were pretreated for 2 h with 100 mg/ml
ranibizumab or 250 mg/ml bevacizumab (stored at 48C for 8 weeks) before 100 ng/ml VEGF165 was added for 24 h. Both inhibitors prevented VEGF-
induced loss of claudin-1.
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Laboratory sciencemembrane was also indicative of a strong and stable barrier
(ﬁgure 5B,C).
Migration of iBREC towards ﬁbronectin was not altered in
the presence of 60 mg/ml ranibizumab as shown by normalised
migration rates of 104%634% versus 100%631% (control). In
contrast, 150 mg/ml bevacizumab strongly and signiﬁcantly
reduced basal migration rates of iBREC (normalised values of
43%627%, p<0.0001 for comparisons with control and ranibi-
zumab-treated cells), indicating VEGF-independent effects of
bevacizumab. Basal proliferation of iBREC (normalised rates of
100%612%) was not signiﬁcantly affected by ranibizumab
(104%612%) or bevacizumab (94%618%).
DISCUSSION
The humanised VEGF-binding antibody bevacizumab is widely
used off-label to treat DME.
5 Although REC are considered the
most important target cells of VEGF in the development and
progression of this disease, in vitro experiments performed to
understand the mechanisms of the therapeutic effects of beva-
cizumab have been focused almost exclusively on non-retinal EC
or RPE cells.
13 15 16 21 In this investigation we used iBREC,
a retinal cell line with the distinct advantage over primary ECs
that contaminating cells of other types cannot be present in the
cultures.
20 Studies with iBREC ideally complement investiga-
tions based on rodent models of diabetes and may even be more
relevant to clinical applications of drugs under investigation,
because of the higher similarity of bovine proteins to their
human counterparts. In our previous studies based on the iBREC
model, we showed that ranibizumab, in addition to efﬁcient
inhibition of VEGF-stimulated proliferation and migration, can
completely restore the VEGF-induced impairment of the endo-
thelial barrier; this provided a rationale for using this antibody
fragment in DME therapy.
41 01 11 4Stimulation of iBREC was
carried out in these experiments, with concentrations of VEGF
similar to those measured in the vitreous ﬂuid of DR patients;
concentrations of ranibizumab and bevacizumab reﬂected values
found to be achievable by standard therapies with these
drugs.
1e5 We conﬁrmed that bevacizumab inhibits VEGF-
induced proliferation but is less efﬁcient than ranibizumab; this
was also observed in experiments with human REC and could be
a consequence of its much lower afﬁnity to VEGF.
12 18 Likewise,
the ability of bevacizumab to re-establish an intact iBREC
barrier that had been deranged by VEGF, was lower than that of
ranibizumab. Despite being observed in vitro, this difference
might be seen as a challenge to the assumption that both drugs
are equivalent in the treatment of DR.
5 Also of potential rele-
vance for its clinical application is the surprising ﬁnding that
bevacizumab repackaged in syringes and stored at 48C for more
Figure 3 Visualisation of bevacizumab internalised by immortalised
bovine retinal endothelial cells (iBREC). iBREC were treated with
bevacizumab (right column) or ranibizumab. After indicated times of
incubation, inhibitors were visualised by immunoﬂuorescence staining
with antibodies against human IgG. Staining of ranibizumab-treated cells
(middle column) was similar to the faint unspeciﬁc signals observed in
control cells kept in standard medium (left column). Incubation with
bevacizumab resulted in strong intracellular staining of iBREC.
Figure 4 Semi-quantitative assessment of bevacizumab and ranibi-
zumab in subcellular fractions of immortalised bovine retinal endothelial
cells (iBREC). (A,B) iBREC were treated for 1 h to 6 days with 250 mg/ml
bevacizumab (A) or 100 mg/ml ranibizumab (B) and whole cell extracts
of 10
5 cells (A) or 3310
5 cells (B) were subjected to western blot
analyses. Deﬁned amounts of both inhibitors were loaded for semi-
quantitative assessment. The band speciﬁc for ranibizumab was most
intense after treatment for 1 day. During prolonged exposure, the
intracellular amount of bevacizumab but not that of ranibizumab
increased. (C,D) iBREC were treated for 1 day with bevacizumab (C) or
ranibizumab (D) in the absence or presence of vascular endothelial
growth factor (VEGF165); subcellular fractions of 2310
4 cells (C) or
5310
4 cells (D) were analysed. Deﬁned amounts of both inhibitors were
loaded for semi-quantitative assessment. Ranibizumab was detected in
the membrane/organelle fraction. In contrast, higher amounts of
bevacizumab were mainly found in the fraction of cytoskeleton proteins.
Localisation was not affected by pretreatment with VEGF165.
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Laboratory sciencethan 2 weeks lost its ability to restore VEGF-induced loss of
claudin-1, an indicator of an intact barrier. In one previous study,
loss of bevacizumab activity was reported to be caused by
freezing and thawing, after which it failed to prevent VEGF-
stimulated increase of permeability of choroidal EC.
21 It has
been suggested that partial inactivation of bevacizumab in
solution might be due to formation of antibody aggregates with
potentially masked binding sites, a process more frequently
observed when the solutions were stored in syringes.
22 23
However, in solutions of bevacizumab used in this study, such
aggregates were undetectable; we assume that partial loss of
activity was more likely caused by yet unidentiﬁed reactions
leading to modiﬁcation of the protein. In contrast to the rever-
sion of a state established during exposure to VEGF for days,
reﬂecting the pathophysiological conditions typical for DME,
prevention of the effects of VEGF on proliferation, migration
and expression of claudin-1 by bevacizumab was not dependent
on the time and conditions of its storage prior to the experi-
ments. Preventing VEGF-induced processes may simply require
lower amounts of an inhibitor, and it is therefore less sensitive to
partial inactivation during storage than reversion of established
states. In accordance with this assumption, preventing VEGF-
induced loss of claudin-1 in iBREC was achieved with much
lower concentrations of an inhibitor of VEGF receptor 2 than
those for restoring VEGF-decreased claudin-1.
14 This suggests
that elimination of VEGF from the extracellular space may not
be sufﬁcient to reverse its long-term effects on ECs and that
additional mechanisms contribute to the therapeutic effects of
drugs like ranibizumab and bevacizumab. Potential second
targets may be secreted factors like VEGF or cell surface mole-
cules on ECs, but internalised drugs may also affect intracellular
processes.
After treatment for 1 day, about 40000 molecules of ranibi-
zumab were calculated to be present inside iBREC. Association
of ranibizumab with the organelle/membrane fraction is in
accordance with the speculation that this substance is intern-
alised by endocytosis to be degraded. Then the constant intra-
cellular amounts of ranibizumab observed during prolonged
exposure can be considered a steady state in which uptake and
degradation of the protein are balanced. In contrast, a higher
amount (w100000 molecules per cell) of bevacizumab measured
after one day in iBREC further increased when the cells were
kept in medium containing the antibody. Most of the accumu-
lated bevacizumab was found associated with the cytoskeleton,
which might be the reason for the surprisingly observed inhi-
bition of basal migration of iBREC. Because serum-free medium
was used in this assay, this inhibitory effect could not be caused
by targeting residual amounts of VEGF. The part of internalised
bevacizumab found in the organelle/membrane fraction could be
degraded like ranibizumab, but this process seems to be not fast
enough to avoid an increase of intracellular amounts. Treatment
of iBREC with VEGF165 did not alter intracellular quantities or
their localisation, indicating that the endocytotic uptake of
ranibizumab or bevacizumab by iBREC is not dependent on
binding to the antigen. This is in accordance with a different
localisation of intracellular VEGF which may be taken up
through other pathways. Whether binding of the constant
region of the antibody bevacizumab to the Fc receptor plays
a role in its internalisation, remains to be investigated.
Neither ranibizumab nor bevacizumab affected the barrier of
iBREC in the absence or presence of VEGF, even when the cells
were exposed to the drugs for several days. This result contrasts
with those of experiments with RPE cells in which ranibizumab
transiently and bevacizumab lastingly increased the perme-
ability, showing that in the two most important cell types
involved in DR and DME, barriers of cell layers and dynamics of
TJs are most likely regulated in different ways.
17 In an overall
assessment of therapeutically relevant processes in the eye, such
differences between alternative drugs and their cell type-speciﬁc
effects have to be taken into consideration.
In this study we showed that the actions of ranibizumab and
bevacizumab on REC were similar but differed in some respects:
bevacizumab inhibited or restored VEGF-induced effects with
a slightly lower efﬁciency than ranibizumab and accumulated in
these cells. Although the barrier properties of REC were not
affected by internalised bevacizumab in our in vitro experi-
ments, adverse effects in vivo cannot be ruled out because more
antibody molecules might accumulate in these cells after
repetitive intravitreal injections. Transient accumulation of
bevacizumab in the RPE has been observed after its intravitreal
injection into the primate eye.
24 This might have some func-
tional consequences as suggested by the ﬁnding that phagocy-
totic uptake of photoreceptor outer segments by porcine RPE
cells is inhibited after long-term exposure to bevacizumab, an
Figure 5 Transendothelial resistance (TER) and localisation of
claudin-1 were not altered by bevacizumab or ranibizumab. Conﬂuent
immortalised bovine retinal endothelial cells (iBREC) were treated with
bevacizumab or ranibizumab for several days. (A) Constantly high TER,
indicative of a stable iBREC barrier, was measured despite the presence
of vascular endothelial growth factor (VEGF) inhibitors during cultivation.
(B) Unchanged expression of claudin-1 and claudin-5 by iBREC treated
for 6 days with VEGF inhibitors was determined by immunoﬂuorescence
staining. (C) Western blot analyses of subcellular fractions of iBREC
treated with VEGF inhibitors for 1 day showed stable expression and
localisations of claudin-1 and claudin-5.
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16 Considering the typical
ages of the DME-patients and duration of treatment, these
results strongly suggest further investigations to exclude
any harmful long-term consequences for retinal cells due to
accumulation of bevacizumab after repetitive injections.
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